drugset
drugset / Trial / NCT05138705

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years

NCT05138705 ↗

Phase 4 Completed 380 enrolled Shanghai Institute Of Biological Products
NaSingle-groupOpen-labelPrevention

Summary

To evaluate the safety and immunogenicity of quadrivalent influenza virus split vaccine in healthy population aged 3-8 years following different immunization procedures.

Timeline

Start
2021-12-14
Primary completion
2022-02-28
Completion
2022-08-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Quadrivalent Influenza Virus Split Vaccine Vaccine 0.5 ml —

Indications

influenza